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Abstract
Metastatic progression is a multistep process that involves tumor growth and survival, motility and invasion, and
subsequent proliferation in an inappropriate environment. The Src protein tyrosine kinase has been implicated in many of
the biochemical pathways that drive these behaviors. Although Src itself is only rarely mutated in human tumors, its
aberrant activity has been noted in various cancers and suggested to serve as a barometer of metastatic potential. With
these features in mind, we examined Src kinase regulation at the structural, enzymatic, and expression levels as a function of
progressively invasive prostate cancer cell lines. Surprisingly, both total Src content and kinase activity decrease with
increasing cell line aggressiveness, an observation that appears to be inconsistent with the well-documented role of Src in
the signaling pathways that drive growth and invasion. However, we do observe a direct correlation between Src kinase
specific activity (total Src kinase activity/total Src content) and metastatic aggressiveness, possibly suggesting that in highly
aggressive cell lines, key signaling enzymes are globally recruited to drive the cancerous phenotype. In addition, although
the expected enhanced phosphorylation of Src at Tyr-416 (activation site) is present in the most aggressive prostate cancer
cell lines, unexpectedly high phosphorylation levels at the Tyr-527 inhibitory site are observed as well. The latter, rather than
representative of inhibited enzyme, is more indicative of primed Src responsive to local phosphorylated binding partners.
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Introduction
The Src protein kinase is the founding member of the Src kinase
subfamily of nonreceptor protein tyrosine kinases. The catalytic
activity of these enzymes is regulated, in part, via phosphorylation
[1]. Specifically, full activation of Src is dependent upon
phosphorylation at Tyr-416. By contrast, Tyr-527 phosphoryla-
tion inhibits catalytic activity, by promoting an intramolecular
interaction with the enzyme’s SH2 (and SH3) domains. Indeed,
the level of phosphorylated Tyr-527, as revealed by Western blot
analysis or immunostaining, is often taken as a measure of inactive
enzyme. For example, Src kinase activity was reported to be up-
regulated in hormone-refractory prostate cancer as assessed by
phosphorylated Tyr-416 content [2]. However, this interpretation
is fraught with danger. Although the low in vitro catalytic activity of
pTyr-527 Src is indisputable, the corresponding activity of the
same enzyme in a biological environment is less certain. Upon
interaction of the SH2 or SH3 domains of the Src enzyme with
other proteins, the inhibitory pTyr-527 residue is released, which
generates fully active pTyr-527 Src [3–5]. Indeed, this process is
recapitulated by short pTyr-containing peptides that, upon
binding to Src’s SH2 domain, disrupt the intramolecular
inhibitory pTyr-527 interaction and thereby activate kinase
activity [6–8]. Consequently, pTyr-527 status is not necessarily
indicative of an inhibited enzyme per se, but rather of an enzyme
that is potentially primed and ready to be ‘‘switched on’’ by
interaction with an appropriate accessory protein. In short, high
pTyr-527 Src levels could represent inhibited enzyme, activated
enzyme, or some variant in-between. This uncertainty highlights
the need to sample Src kinase directly via its ability to phosphorylate
a target substrate. In addition to phosphorylation, the Src kinase is
regulated at the protein level via ubiquitination and thus
degradation by the proteasome-mediated pathway [9]. Conse-
quently, in much the same way that phosphorylation status is a
questionable harbinger of kinase activity, mRNA levels are not
necessarily indicative of Src kinase content or activity.
Src is strongly implicated in the pathways that control many of
the characteristic cell behaviors responsible for tumor invasion and
progression. For example, Src mediates adhesion and cytoskeleton
dynamics and thereby controls cell migration [10,11]. Invasive
migration is augmented by a Src-dependent epithelial-mesenchy-
mal transition [12] and activation of matrix-degrading proteases
[13–16]. Src phosphorylation of caspase 8 is antiapoptotic [17]
whereas Src-mediated STAT activation promotes cell growth and
survival [9]. In short, Src is implicated in a plethora of pathways
that are up-regulated in many of the most aggressive and invasive
forms of cancer. However, since Src is only rarely mutated in
human tumors, aberrant Src behavior is most often a consequence
of its abnormal regulation. We have examined Src kinase
regulation at the structural, catalytic, and expression levels across
a platform of prostate cancer cell lines that vary in behavior from
noninvasive to highly invasive and from androgen-dependent to
androgen-independent. Surprisingly, we found that Src catalytic
activity and protein levels are significantly reduced in the most
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aggressive cell lines. By contrast, these aggressive cell lines display
high Src specific activity and enhanced levels of phosphorylation at
Tyr-527 (the so-called inhibitory site) relative to their less
aggressive counterparts. These results are discussed in the context
of the mechanism of Src activity in highly proliferative environ-
ments.
Results
Design and Synthesis of the Src Kinase Sensor
Based, in part, on a Src substrate sequence identified from an
oriented peptide library [18], we constructed the fluorophore-
labelled sequence: 5-FAM-Orn(Ac)-Glu-Glu-Glu-Ile-Tyr-Gly-
Glu-Phe-Orn(Ac)-amide (1), where Tyr is the site of phosphory-
lation. In addition, ornithine (Orn) residues were placed on each
terminus of the peptide sequence, in the event that the peptide
proved to display poor selectivity for Src versus other protein
kinases. We’ve previously shown that side chain modification of
active site-directed peptides with unnatural substituents can
dramatically enhance the selectivity for the target protein kinase
(vide infra) [19–25]. Both the non-phosphorylated and the
phosphorylated forms [5-FAM-Orn(Ac)-Glu-Glu-Glu-Ile-pTyr-
Gly-Glu-Phe-Orn(Ac)-amide (2)] of the peptide were prepared
via solid-phase peptide synthesis. 5-FAM (5-carboxyfluorescein)
was chosen as the fluorophore for substrate and product detection
by LIF.
The separation of the non-phosphorylated substrate and the
phosphorylated product by CE-LIF is shown in Fig. 1A. A 1:1
mixture of the peptides was loaded into the capillary. Under the
separation conditions described in Materials and Methods,
substrate peptide 1 emerges at 240 sec, whereas the phosphory-
lated product 2 appears at 290 sec. Growth of the latter was
monitored, as a function of time, by incubating the substrate (1)
with active Src kinase. The 290 sec peak was confirmed to be the
phosphorylated product by spiking with synthetic phospho-peptide
2. The kinetics of phosphorylation was obtained by evaluating
collected time point samples via CE-LIF and quantifying the
extent of phosphorylation via integration of the individual peaks.
Peptide 1 phosphorylation is essentially complete within 3 min
under the assay conditions that employed pure Src enzyme
(Fig. 1B). By contrast, subsequent experiments in cell lysates (vide
infra) proceed at a more leisurely pace. In the latter case, initial rate
kinetics (,10% peptide phosphorylation) were acquired within
10 min of cell lysate incubation.
Stability of the Src Kinase Peptide Substrate 1 in Prostate
Cell Lysates
Peptides commonly suffer protease-catalyzed degradation in
cells as well as in cell lysates. Consequently, prior to examining Src
kinase-catalyzed phosphorylation of peptide 1 with lysates, we
monitored the stability of the peptide as a function of time. Cells
were lysed using Pierce’s M-PER mammalian lysis buffer and, in
the absence of ATP and Mg2+ (i.e. no observable kinase activity),
the lysate was added to peptide 1. Only approximately 10% of the
peptide is degraded after 1 h (Table S1). Since the phosphoryla-
tion rate is measured within 10 min of incubation (Fig. S1), the
peptide is sufficiently stable for our needs.
Assessment of Src Activity in Prostate Cell Line Lysates
Our initial studies focused on the non-invasive immortalized
normal prostate epithelial cell lines PZ-HPV-7 and RWPE1 and
the highly invasive CaP cell lines DU145 and PC3. We also
investigated Src activity in the non-metastatic CWR22Rv1 cell
line, which exhibits androgen-independent growth, a characteristic
behavior of advanced stage CaP [26] correlated with the Src
kinase [2]. We assessed the initial rate kinetics (i.e. ,10% of
product formation) of peptide phosphorylation (Fig. S1) and were
surprised to find that Src kinase activity (as a function of total
protein extract amount) is significantly lower in aggressive prostate
cancer cell lines (CWR22Rv1, DU145 and PC3) than the non-
cancer prostate cell lines (PZ-HPV-7 and RWPE1) (Fig. 2; grey
bars; P,0.001). This general trend is at variance with the general
notion that high Src activity correlates with prostate cell line
aggressiveness (i.e. invasive behavior and androgen-independent
growth). Previous reports have noted that high levels of pTyr-416
are present in the most aggressive CaPs and it has been assumed,
throughout the literature, that pTyr-416 and Src activity directly
correlate with one another. One possible conclusion derived from
our data is that the generally accepted notion that pTyr-416 levels
serve as a barometer of Src activity is faulty. However, we
investigated whether there might be alternative explanations for
the unexpected relationship between Src activity and cell line
aggressiveness. One possibility is that the Src substrate 1 is
phosphorylated by other protein tyrosine kinases thereby render-
ing the apparent inverse relationship between Src activity and cell
aggressiveness misleading.
Assessment of the Selectivity of Peptide 1 for Src in
Prostate Cell Lines
We examined the Src-selectivity of 1 using CaP cell lysates
depleted of Src (Fig. S2). Although Src-free cell lysates are able to
phosphorylate peptide 1, they do so to a much lesser extent
(,30%) than with whole cell lysates containing Src (Fig. 2, white
bars). The contaminating tyrosine kinases that may be responsible
for the low level of peptide 1 phosphorylation in the absence of Src
could be one or more of the eight other members of the Src family
kinases (SFK). Indeed, several SFK family members, such as Fyn,
Brk, Lyn Lck and Yes are known to present in prostate cell lines
[27]. Nonetheless, given the relatively modest level of peptide 1
phosphorylation by Src-free lysates, we decided that peptide 1 is,
for our present needs, sufficiently Src selective.
We also assessed the ability of the Src peptide 1/CE-LIF
method to detect Src activity by using a combination of two known
Src inhibitors. Imatinib (marketed as Gleevec), which is used to
treat chronic myelogenous leukemia and other cancers, is an Abl-
selective inhibitor with demonstrated weak anti-Src activity.
Imatinib blocks kinase activity by serving as a competitive
inhibitor of ATP. Like imatinib, saracatinib (AZD0530) is a
competitive inhibitor of ATP, but displays a high selectivity and
robust potency for Src. For example, the IC50 values of imatinib
and saracatinib with isolated Src enzyme are 24.4 mM [28] and
2.7 nM [29], respectively. Using DU145 cell lysates, we found that
the potent Src inhibitor saracatinib blocks peptide 1 phosphory-
lation with a submicromolar IC50 (0.3560.08 mM) whereas the
correspondingly poor Src inhibitor imatinib displays an IC50 that is
in excess of 100 mM (Fig. S3). These results are consistent with
notion, exemplified by the Src depletion experiments that the Src
peptide 1/CE-LIF method serves as an efficient and selective Src
activity detection modality. Src kinase activity was also assessed in
live single cells, both in the absence and presence of imatinib and
saracatinib (Fig. S3).
Src Expression Levels and Phosphorylation Status in
Prostate Cell Lines
Src activity is higher in non-aggressive cell lines and lower in
aggressive cell lines (Fig. 2), which is inconsistent with the general
notion that Src plays a key role in carcinogenesis, metastasis, and
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the transition to the androgen-independent state. However, it
occurred to us that total Src content may vary from one cell line to
the next, which could the apparent (but misleading) inverse
relationship between Src activity and CaP aggressiveness.
Src content was quantified by western blot analysis (Fig. 3A) and
normalized relative to a-tubulin. We found that the invasive cell
lines, as well as the androgen-independent cell line, display less Src
than the corresponding non-invasive, androgen-dependent cell
lines (Fig. 3B, p,0.001). With this data in hand, we subsequently
plotted Src specific activity (i.e. total Src activity/total Src content)
versus cell line aggressiveness. The latter reveals Src specific
activity is significantly higher in aggressive cell lines (CWR22Rv1,
DU145, PC3) than in non-aggressive/normal cell lines (PZ-HPV-
7, RWPE1) (Fig. 4, p = 0.0015).
We also examined what relationship, if any, exists between the
levels of pTyr-416 and pTyr-527 Src and Src specific activity.
Figure 1. Assessment of Src kinase catalytic activity. (a) CE-LIF separation and visualization of the Src peptide substrate 1 and its chemically
synthesized phosphorylated counterpart 2. (b) Src kinase-catalyzed phosphorylation of peptide 1 as a function of time as assessed by CE-LIF.
doi:10.1371/journal.pone.0048867.g001
Figure 2. Src kinase activity in non-invasive (PZ-HPV-7, RWPE1), invasive (DU145, PC3), and androgen-independent (CWR22Rv1)
cell lines. Grey bars are phosphorylation rates of peptide 1 by whole cell lysates (normalized by total protein extract amount). White bars are
phosphorylation rates by cell lysates due to Src kinase alone after subtracting non-Src background phosphorylation of 1. Comparison between non-
cancer (PZ-HPV-7, RPWE1) and aggressive cancer cell lines (CWR22Rv1, DU145, PC3) showed significant lowered levels of Src kinase activity associated
with the later (p,0.001). All experiments were performed at least in triplicate. Error bars are SEM.
doi:10.1371/journal.pone.0048867.g002
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Phosphorylation at 416 is required for full activation of Src activity
whereas phosphorylation at Tyr-527 is inhibitory due to the
formation of an intramolecular interaction that blocks Src kinase
activity [1]. pTyr-416 fractional levels (pTyr-416/total Src
content) (Fig. 5A) is highly correlated with specific Src activity
(Fig. 4) (r = 0.89), suggesting that pTyr-416 content is a good
barometer of Src activity and cell line aggressiveness (Fig. 5A).
However, as noted below, this correlation does not extend to all
cell lines. By contrast, pTyr-527 content, a presumed indicator of
inhibited Src, is more pronounced in aggressive cell lines (Fig. 5B).
Figure 3. Src expression levels in non-invasive (PZ-HPV-7, RWPE1), androgen-independent (CWR22Rv1), and invasive (DU145, PC3)
cell lines. (a) Prostate cell lysates were probed for total Src, pY416 Src and pY527 Src, where a-tubulin was used as the loading control. (b) Intensities
of each band from the western blots were measured and normalized to the corresponding a-tubulin control, and then compared to cell line RWPE1
(RWPE1 as 1). Comparison between non-cancer (PZ-HPV-7, RPWE1) and aggressive cancer cell lines (CWR22Rv1, DU145, PC3) showed significant
lowered levels of Src expression in the latter (p,0.001). Data are representative of at least three independent experiments and are mean with SEM.
doi:10.1371/journal.pone.0048867.g003
Figure 4. Src specific activity in non-invasive (PZ-HVP-7, RWPE1), androgen-independent (CWR22Rv1), and invasive (DU145, PC3)
cell lines. Src kinase specific activity was calculated by dividing Src activity (Fig. 2) by total Src protein content (Fig. 3). Src specific activity is
significantly higher in aggressive than in non-cancer cell lines (P,0.0001). Error bars are SEM.
doi:10.1371/journal.pone.0048867.g004
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This observation is inconsistent with the general notion that
activated Src correlates with cell line aggressiveness. In short, the
phosphorylation status of Tyr-416 and Tyr-527, taken together, do
not provide a consistent picture of Src activity across an array of
CaP cell lines.
Src Activity, Expression Levels, and Phosphorylation
Status in RWPE1-Derived Prostate Cell Lines
In addition to the standard prostate cell lines evaluated in Fig. 2,
3, 4, and 5, we evaluated a series of cell lines that were derived by
exposure of RWPE1 to N-methyl-N-nitrosourea. Cell lines of
increasing invasiveness have been identified via a series of in vitro
and in vivo selection experiments: RWPE1, WPE1-NA22, WPE1-
NB14, WPE1-NB11 and WPE1-NB26 [30]. This series displays
Src kinase activity and aggressiveness correlations analogous to
those described above for the standard prostate cell lines. First,
total Src activity displays a significant decreasing trend (p = 0.018)
as a function of increasing cell line aggressiveness (Fig. 6A).
Second, with the exception of WPE1-NB26, total Src content also
linearly decreases (p = 0.01) as a function of cell line aggressiveness
(Fig. 6B and Fig. S5). Third, again with the exception of WPE1-
NB26, specific Src kinase activity (Src kinase activity/total Src
content) displays a significant linear increasing trend (p,0.001) as
a function of increasing cell line aggressiveness (Fig. 6C). Finally, in
sharp contrast to the results displayed in Fig. 5A, the correlation
between pTyr-416 fractional levels (pTyr-416/total Src content)
and Src specific activity is weak (r = 0.58), suggesting that it is
dangerous to solely rely on pTyr-416 content as a barometer of Src
activity (Fig. 6D). Interestingly, we do observe a very strong
correlation with respect to fractional pTyr527 content and specific
Src activity in RWPE1 series of cell lines (Fig. S6, r = 0.99), similar
to that in Fig. 5B (r = 0.88).
Discussion
Generic ELISA- [31] and c-32P-ATP-based [32] methods are
two of the most common strategies used for assessing activity with
pure enzyme under in vitro conditions. In addition, fluorophore-
labeled peptides [33–37], as well as GFP-based proteins [38,39],
have been described that exhibit a fluorescent response to
phosphorylation, thereby allowing Src kinase activity to be
continuously sampled in live cells via fluorescent microscopy.
Although these technologies furnish a window into the biochem-
ical basis of cell behavior, they are less readily translated into a
routine, cross-platform methodology (pure enzyme, cell lysates,
and intact cells) that can also be applied to the limited number of
primary cells available in patient samples. In this regard, CE is an
ultrasensitive method by which small amounts of analytes are
separated and quantified, via the application of an electric field
and subsequent detection of the analytes [40]. Since the Src kinase
catalyzes the transfer of the c-phosphoryl group from ATP to the
tyrosine residue of the substrate, the charge difference between
substrate and product should enable these species to be separated,
visualized, and quantified via a shift in electrophoretic mobility
[41–43]. Indeed, the fluorescein-substituted Src substrate 1 and its
phosphorylated counterpart are readily differentiated upon
exposure to both pure Src kinase (Fig. 1) and prostate cell lysates
(Fig. 2). In the latter case, in nearly all cell lines, the vast majority
of observed phosphotransferase activity (.70%) is due to the Src
kinase (Fig. 2). The CE assay was further validated by examining
the Src inhibitory potency of saracatinib and imatinib, where the
latter is four orders of magnitude weaker (IC50 = 24.4 mM) than the
former (IC50 = 2.7 nM) against pure enzyme [28,29]. Consistent
with these results, we observed a difference in inhibitory potency
between saracatinib (IC50 = 0.3560.08 mM) and imatinib
(.100 mM) for Src in DU145 cell lysates analogous to the
reported difference under simple buffer conditions. Finally, we
investigated whether the CE strategy could be used to observe Src
activity and inhibition in single cells (Fig. S4). DU145 cells were
microinjected with Src substrate 1, the cells subsequently
incubated for 2 min, individually lysed using a focused Nd:YAG
laser, and then the lysate from each cell separately electropho-
resed. The formation of the phosphopeptide product was observed
from cells that had not been preincubated with inhibitor (1462%
of total peptide content) or in cells preincubated with 1 mM of the
weak inhibitor imatinib (IC50.100 mM; 1563% of total peptide
Figure 5. Src phosphorylation status in non-invasive (PZ-HVP-7, RWPE1), androgen-independent (CWR22Rv1), and invasive
(DU145, PC3) cell lines. (a) pY416 levels were derived from the band intensities in the western blots (Fig. 3A), normalized to the corresponding a-
tubulin control, and then compared to cell line RWPE1 (RWPE1 as 1). (b) pY527 levels were derived from the band intensities in the western blots (Fig.
3A), normalized to the corresponding a-tubulin control, and then compared to cell line RWPE1 (RWPE1 as 1). Data are representative of at least three
independent experiments and are shown as mean with SEM. p values are indicated.
doi:10.1371/journal.pone.0048867.g005
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content). By contrast, no peptide phosphorylation was observed in
cells that had been preincubated with 1 mM of the potent inhibitor
saracatinib (IC50 = 0.3560.08 mM).
With the ability to sample Src activity using purified enzyme, in
cell lysates, and in single cells, we examined Src activity from
noninvasive, invasive, and androgen-independent prostate cell
lines (Fig. 2). Unexpectedly, we found that Src phosphotransferase
activity is highest in the noninvasive cell lines, which appears to be
contrary to the general notion that Src plays an important role in
potentiating metastatic potential and the transition to and
maintenance of androgen-independent growth in prostate cancer.
However, it occurred to us that Src kinase levels might differ across
cell lines. Once again, unexpectedly, we found that invasive and
androgen-independent cell lines exhibit significantly less Src than
their non-invasive androgen-dependent counterparts (Fig. 3). On
the other hand, the ratio of Src activity to Src content (specific
activity) revealed that aggressive and androgen-independent cell
lines display a higher Src specific activity than non-aggressive
androgen-dependent cell lines (Fig. 4). Furthermore, this trend
holds for the series of N-methyl-N-nitrosourea cell lines derived
from RWPE1 (from the peripheral zone of a normal human
prostate). Specifically, we observed decreased total Src activity and
Src content, and increased Src specific activity as a function of
increasing cell line invasiveness (RWPE1,WPE1-NA22,WPE1-
NB14,WPE1-B11) (Fig. 6A-B). We do note one exception to this
correlation, namely the most aggressive RWPE1-derived cell line,
WPE1-NB26. The latter has received significant attention due to
its highly invasive phenotype [30,44–53]. Using total Src content
and specific activity as measures of aggressiveness, we would have
assigned a non-invasive phenotype to WPE1-NB26 (i.e. similar to
that of the parent cell line RWPE1). However, since this is clearly
incorrect, the aggressiveness associated with this N-methyl-N-
nitrosourea cell line may be due, at least in part, to mechanisms
that are independent of Src signaling.
Figure 6. Src-catalyzed phosphorylation rates, Src protein content, and Src phosphorylation status in the RWPE1-derived cell lines.
Increasing invasive ability is plotted along the x-axis. (a) Grey bars are phosphorylation rates of peptide 1 by whole cell lysates (normalized by total
protein content). White bars are phosphorylation rates by cell lysates due to Src kinase alone after subtracting non-Src background phosphorylation
of 1. (b) Total Src content as determined by western blot analysis (Fig. S5) (c) Src kinase specific activity as assessed by measured Src activity (Fig. 6A)
divided total Src protein content (Fig. 6B). (d) pY416 levels were derived from the band intensities in the western blots (Fig. S4), normalized to the
corresponding a-tubulin control, and then compared to cell line RWPE1 (RWPE1 as 1). Data are representative of at least three independent
experiments and are shown as mean with SEM.
doi:10.1371/journal.pone.0048867.g006
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Why is the total Src content decreased in the most aggressive
cell lines? One possible explanation is the known sensitivity of
activated Src, relative to its non-activated counterpart, to
ubiquitin-mediated degradation [54,55]. Consequently, cell lines
that are under intense activated Src pressure might, ironically,
display lower Src content than less aggressive cells. In addition,
two recent studies suggest a micro RNA (miR)-dependent
mechanism by which Src levels are regulated. Bhatnagar et al
have shown that the more invasive the prostate cell line the higher
the miR-205 level [48]. miR-205 is known to downregulate Src
expression [56]. Our observation that Src levels are lower in
aggressive prostate cell lines is consistent with both ubiquitin and
miRNA mechanisms. In addition, the higher specific activity in the
most aggressive cell lines indicates that, in these cells, although
there is less Src present, a greater fraction of it resides in the active
form.
Src phosphorylation status has been assumed to correlate with
activity where pTyr-416 is taken as active and pTyr-527 as
inactive forms of the enzyme. With this in mind, we measured the
levels of pTyr-416 via Western blot analysis and plotted pTyr-416
Src/total Src (fractional pTyr-416) versus cell line aggressiveness.
As is evident from Fig. 5A and 6D, highly aggressive cell lines
display a higher ratio of pTyr-416 to total Src than their
nonaggressive counterparts. This is consistent with a recent report
by Evans and colleagues demonstrating that the Src inhibitor
saracatinib is most effective against prostate cell lines that have the
highest ratio of active-to-total Src [57]. In the latter study, ‘‘active
Src’’ was taken to be pTyr-416 Src. These investigators also
reported that cells with the lowest (pTyr-416 Src/total Src) ratios
express the most Src.
A high pTyr-527/total Src ratio should be, according to the
conventional model, indicative of an overall lower fraction of
active enzyme. However, we’ve found that this ratio is higher in
aggressive lines as well (Fig. 5B and Fig. S5). One possible
explanation for this unexpected result is the known ability of the
pTyr-527 Src enzyme to be activated by phosphorylated peptides
and proteins. In short, although pTyr-527 Src is inactive in its
isolated, purified form, the opposite may be true when potential
phosphorylated binding partners are present. Consequently, we
conclude that pTyr-527 Src levels are not a useful barometer of
inactive Src and, rather, may actually be a more appropriate
prognosticator of Src activity. As an aside, we note that the
Western blots employed in this study to detect Src phosphorylation
status used large cell populations. However, recent advances,
driven by CE technology, enable the phosphorylation status of
proteins to be resolved and detected from as few as 25 cells [58].
Indeed, CE as a microscale Western blotting system has received
significant attention [59]. Consequently, it may ultimately be
feasible to simultaneously sample the levels of specific enzyme
phospho-isoforms as well as enzyme activity in a few cells using CE
technology.
There has been and continues to be a herculean effort to
identify CaP markers that correlate with heritability as well as
acquired somatic mutations. For example, more than 40
susceptibility loci have been assigned to approximately 25% of
the heritable risk. [60] In addition, both coding region and whole
genome analyses have been conducted to identify genetic
aberrations that correlate with somatically acquired CaP. For
example, a recent whole genome study was performed using tumor
samples from patients with aggressive CaP. These investigators
identified nearly 4000 somatic base mutations and 90 chromo-
somal rearrangements per tumor, as well as correlations between
an array of rearrangement breakpoints and various epigenetic
marks. [61] The authors note that a ‘‘spectrum of mechanisms
direct prostate cancer genesis and progression’’ [61] and thus no
single change in enzymatic activity is accountable for the onset,
progression, and/or aggressiveness of the disease. For example, the
complex genomic rearrangements prevalent in CaP are thought to
impinge on the deletion and amplification of an array of genes
encoding known tumor suppressors and oncogenes, respectively.
Nonetheless, our data does suggest that Src specific activity may
serve as a barometer of CaP aggressiveness. This is likely a
consequence of the fact that Src itself is a key participant in
pathways that mediate cell growth and motility, which in turn may
reflect the massive and complex genomic structural changes
prevalent in CaP. In addition, although we’ve found that pTyr-
416 Src/total Src is a reliable indicator of Src specific activity, the
results with pTyr-527 are, at first glance, unexpected. Phosphor-
ylated Tyr-527 is generally considered to be reflective of inactive
enzyme. However, we’ve found that the ratio of pTyr-527/total
Src is a poor indicator of inactive Src in CaP cell lines. Rather, the
latter ratio appears to be a much better predictor of active Src.
From a mechanistic point of view, this might reflect the presence
of phosphorylated proteins that can associate with (via Src’s SH2
domain) and thereby rapidly activate the inhibited enzyme.
Consequently, the activity status of pTyr-527 Src should be
viewed as ‘‘primed for activity’’ rather than statically inactive.
In summary, we have developed a sensitive and selective Src
kinase activity sensing system. Using a series of nonaggressive,
aggressive, and androgen-independent prostate cell lines, we’ve
found that total Src activity decreases as a function of increasing
prostate cell line aggressiveness. However, this unexpected (and
ultimately misleading) observation is a consequence of a corre-
sponding decrease in total Src content in the more aggressive cell
lines. When the latter is taken into account, a direct correlation
exists between cellular aggressiveness and the fraction of cellular
Src present in the active state.
Materials and Methods
Peptide Synthesis
Common analytical grade reagents were purchased from Fisher
or Sigma-Aldrich. Common amino acids, O-(1H-6-chlorobenzo-
triazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
(HCTU), N-Hydroxybenzotriazole (HOBT) and TGR resins were
obtained from NovaBiochem. Fmoc-Orn(Aloc)-OH was obtained
from Bachem. 5-carboxyfluorescein (5-FAM) was purchased from
Anaspec. The non-phosphorylated peptide–resin Fmoc-Orn(A-
loc)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Tyr(tBu)-Gly-
Glu(OtBu)-Phe-Orn(Aloc)-amide-Resin and the phosphorylated
peptide–resin Fmoc-Orn(Aloc)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-
Ile-Tyr(PO(OBzl)OH)-Gly-Glu(OtBu)-Phe-Orn(Aloc)-amide-Res-
in were synthesized using a standard Fmoc peptide synthesis
protocol on the Prelude automatic peptide synthesizer (Protein
Technologies). Amino acid (5 equiv), HCTU (5 equiv) and DIPEA
(10 equiv) were mixed with resin in DMF and reacted for 10 min
at room temperature. Fmoc deprotection was achieved using 20%
piperidine in DMF for 20 min. The Aloc protecting group on the
Orn residues was selectively removed with Pd(PPH3)4 (3 equiv) in
CHCl3/AcOH/N-methylmorpholine (37:2:1). The Orn residues
were then acetylated using acetic anhydride/DIPEA (4:1) and the
N-terminal Fmoc protecting group was subsequently removed.
The free N-terminus was then exposed to 5-FAM (5 equiv),
HOBT (10 equiv) and N,N’-Diisopropylcarbodiimide (DIC, 15
equiv) in DMF overnight, and incubated with 30% piperidine for
15 min. The peptides were cleaved with TFA/H2O/TIS
(triisopropylsilane) (95:2.5:2.5) and purified via HPLC (Waters),
and their structures confirmed by ESI-Mass Spectrometry (Agilent
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Technologies). C81H97N13O27 (peptide 1) Exact Mass calculated
for 1683.7, found (ESI+) 843.0 (M+2H)2+, 562.5 (M+3H)3+ and
C81H98N13O30P (peptide 2) Exact Mass calculated 1763.6, found
(ESI+) 883.0 (M+2H)2+.
Western Blots
Primary antibodies Src (36D10): #2109, Yes: #2734, Phospho-
Src Family (Tyr416): #2101, Phospho-Src (Tyr527): #2105, and
a-tubulin (DM1A): #3873 were purchased from Cell Signaling
Technology; anti-Fyn: 610163 and anti-Lck: 551047 were
purchased from BD Pharmingen Biosciences; anti-Lyn (H-6): sc-
7274 was obtained from Santa Cruz Biotechnology. Secondary
antibodies were obtained from GE Healthcare. SDS-PAGE gel
electrophoresis was performed using NuPage 4–12% Bis-Tris
precast gel (Invitrogen), running at 200 V for 50–60 min. Gels
were transferred using iBlot dry blotting system (Invitrogen) for
7 min. Blocking, antibody incubation, and washes were performed
on SNAPid protein detection system (Millipore). Blots were
detected by Amersham ECL Plus (GE Healthcare) and chemilu-
minescent images were obtained by the FluoChemFC2 system
(Alpha Innotech). Band densitometry was performed using Alpha-
View software. The number of western blots reported for each
data point in Figs. 3B, 4, 5, 6B–D was $3.
Immunodepletion of Src Kinase from Cell Lysates
Src was captured by incubating cell lysate (500 mg)-antibody
[5 mg; Src (36D10): 2109] mixtures with Pierce protein A/G
agarose (Pierce Classic IP kit); and a BSA (5 mg) control was mixed
with Pierce control agarose resin for 1 h at 4uC. Both treatments
(with antibodies and with BSA) were separately repeated (3 h
exposure time to antibodies/BSA and 1 h agarose-capture).
Finally, the pre-cleared lysate was collected and concentrated
using a Vivaspin 500 centrifugal concentrator, 10 kD (GE
Healthcare) for western blot analysis and kinase assays.
Capillary Electrophoresis
Capillary electrophoresis was performed on a ProteomeLab
PA800 system equipped with a laser-induced fluorescence (LIF)
detector (Beckman Coulter). The LIF was excited using the
488 nm argon laser. A fused-silica capillary (30/20 cm total/
effective length, 50/360 mm inner/outer diameter) was used for
separation (Polymicro Technologies). Prior to installation, capil-
laries were pretreated with 0.1 M NaOH for 12 h, distilled water
for 1 h, 0.1 M HCl for 6 h and water again for 12 h. The samples
were hydrodynamically injected and separated at 25uC at a
constant voltage of 12 kV. The running buffer was 100 mM
Borate/100 mM SDS buffer at pH 7.7. Before each run, the
capillary was rinsed with 0.1 M NaOH, distilled water, and then
the running buffer for 2 min under 20 psi pressure. Data was
collected and analyzed using 32 Karat Software (Version 8.0,
Beckman Coulter).
Cell Culture
All cell lines were acquired from ATCC and grown in a
humidified incubator at 37uC with 5% CO2. PZ-HPV-7, RWPE1,
WPE1-NA22, WPE1-NB14, WPE1-NB11 and WPE1-NB26 cell
lines were cultured in Keratinocyte Serum Free Medium (K-SFM)
supplied with 0.05 mg/mL bovine pituitary extract (BPE) and
5 ng/mL epidermal growth factor (EGF) (all provided as a kit
from Invitrogen), and 1% penicillin/streptomycin (P/S; Invitro-
gen). CWR22Rv1 cells were cultured in RPMI-1640 medium
(Invitrogen) supplemented with 10% heat-inactivated fetal bovine
serum (HI-FBS, Invitrogen) and 1% P/S. DU145 cells were
cultured in Eagle’s Minimum Essential Medium (EMEM, ATCC)
supplemented with 10% HI-FBS and 1% P/S. PC3 cells were
cultured in F-12K medium (ATCC) supplemented with 10% HI-
FBS and 1% P/S. Cell lysates were prepared as follows: confluent
cells were first trypsinized and collected into 15 mL tubes in the
presence of FBS-containing buffer or medium and then washed
(3X) with ice cold DPBS buffer. The cells were lysed using M-PER
mammalian protein extraction reagent mixed with 5/100 (v/v)
Halt protease and phosphatase inhibitor cocktail EDTA-free
(Thermo Fisher Scientific) for 10 min at 4uC. Cell debris was
removed by centrifuging samples at 14,000 x g for 10 min at 4uC.
The total protein concentrations were determined using Dc
Protein assay (Bio-Rad).
Protein Kinase Phosphoryl Transfer Activity via Capillary
Electrophoresis
The pure enzyme phosphorylation assays were performed with
a total volume of 40 mL from the following stock solutions: 30.9 mL
of H2O, 0.5 mL of 1.14 mM substrate stock solution, 4 mL of 10X
Src kinase reaction buffer (80 mM MOPS, 2 mM EDTA, 40 mM
MgCl2, pH 7.0), 0.6 mL of 100 ng/mL active Src kinase (Milli-
pore), 4 mL of 10 mM ATP. Final concentration of the assay
solution was 8 mM MOPS, 0.2 mM EDTA, 4 mM MgCl2,
1.5 ng/mL Src kinase, 14.25 mM substrate, and 1 mM ATP.
Assays were initiated by adding ATP. At each time point, 2 mL of
the reaction mixture was removed and diluted with 8 mL 0.1 M
HCl to stop the reaction. Cell lysate phosphorylation assays were
performed similarly as described above using the following
conditions: 2.5 mg/mL cell lysate, 6.75 mM Tris (pH 7.5), 1 mM
ATP, 4 mM MgCl2, 57 mM substrate. Assays were initiated by
adding substrate. Total protein content was used as the internal
normalization of all cell extracts.
Single Cell Capillary Electrophoresis
Custom made cell chambers were prepared by utilizing
polydimethyl siloxane (PDMS, Sylgard 184) to glue a silicon O-
ring to a glass coverslip (Fisher). The day prior to use, DU145 cells
in suspension were diluted in 500 mL of complete media, plated on
the chamber, and incubated in a 5% CO2 humidified incubator at
37uC. Single cell capillary electrophoresis was performed using a
custom-made CE-LIF system, as described previously [62,63].
Briefly, capillaries (30 mm inner diameter, 360 mm outer diameter,
total length 38 cm with an effective length 21.5 cm) were
conditioned with 0.1 M NaOH for 12 h, distilled water for 1 h,
0.1 M HCl for 6 h and distilled water again for 12 h. To initiate
electrophoresis, the inlet reservoir was held at ground and a
voltage of 210 kV was applied to the outlet. The electrophoretic
buffer was 300 mM Borate buffer at pH 7.5. Each new chamber
of cells was first washed with a constant flow of extracellular buffer
(ECB; 135 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2,
and 10 mM HEPES, pH 7.4, 25uC) for 4 min. Microinjection of
DU145 cells was performed using an Eppendorf Transjector 5246
and InjectMan system. 114 mM peptide 1 and 90X phosphatase
inhibitor cocktail mixture (diluted from 100X phosphatase
inhibitor cocktail 2, Sigma-Aldrich) was microinjected into a
single cell (200 hPa, 1 s). For cells not treated with Src inhibitor,
the ECB flow was kept on until 20 s after microinjection. For
inhibitor-treated cells, the ECB flow was halted and replaced with
1 mL of inhibitor-containing ECB for 5 min. The ECB flow was
turned on (40 s total) after microinjection to remove any residual
peptides from the extracellular environment. The microinjected
cell was incubated for 2 min prior to lysis by a focused Nd:YAG
laser [64]. The lysate from the single cell was immediately loaded
onto the capillary via electrokinetic injection and electrophoresed.
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Data was collected with custom software (LabVIEW 9.0.1,
National Instruments) and analyzed by Origin (version 7.5,
OriginLab Corporation).
Statistical Analysis
Differences between non-cancer cells (PZ-HPV-7, RWPE1) and
aggressive cancer cells (CWR22Rv1, DU145, PC3) were com-
pared using the 2-tailed Student’s t-test, and a P-value ,0.05 was
considered statistically significant. Simple regression test with
introduced indicator variable as 4,3,2,1,0 was performed to study
the linear trend among RWPE1 series of cell lines, and a P-value
,0.05 was considered statistically significant. Correlations be-
tween specific Src activity (total Src activity/total Src content) and
phosphorylation status of Src (pTyr-416 Src/total Src or pTyr-527
Src/total Src) were compared using Pearson’s correlation. A
correlation coefficient r.0.9 was considered very highly correlat-
ed; 0.7,r,0.9 was considered highly correlated; 0.5,r,0.7 was
considered moderately correlated.
Supporting Information
Figure S1 Phosphorylation kinetics of peptide 1 by
lysates from nine prostate cell lines.
(TIF)
Figure S2 (a) Western blots of Src kinase from prostate cell line
lysates and (b) validation of the antiSrc antibody.
(TIF)
Figure S3 Normalized Src activity (where 1.0 is activity
in the absence of inhibitor) in DU145 lysates versus log
(a) [saracatinib] and (b) [imatinib] (mM).
(TIF)
Figure S4 Single cell analysis of Src kinase activity in
DU145 cells by CE. (a) Cells exposed to standard media, (c)
standard media and saracatinib/AZD0530 (1 mM), and (e)
standard media and imatinib (1 mM). All cells were subsequently
microinjected with Src kinase sensor 1, incubated for 2 min, lysed
via sonication, the lysate loaded onto the capillary via electroki-
netic injection, and electrophoresed. Electropherograms (a), (c),
and (e) are representative of results where n = 5 for each
experiment. The small peak at 160 s is a component present in
the media. Peptide 1 is the large peak observed approximately
100 s prior to that of the corresponding phosphopeptide. Plot (b) is
the control for (a): lysate from cells were exposed to standard
media spiked with synthetically prepared phosphopeptide 2; Plot
(d) is the control for (c): lysate from cells exposed to standard media
spiked with peptide 1 and phosphopeptide 2; Plot (f) is the control
for (e): lysate from cells exposed to standard media spiked with
peptide 1 and phosphopeptide 2. Controls were run either
immediately prior to or following the corresponding experiments
in (a), (c), and (e).
(TIF)
Figure S5 Total Src content and phosphorylation status
in prostate cell lines.
(TIF)
Figure S6 Src pY527 status in the RWPE1-derived cell
lines with increasing invasive ability plotted along the x-
axis.
(TIF)
Table S1 Stability of the Src sensor in prostate cell lysates.
(PDF)
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